US Patent

US12268725 — Composition of BL-8040

Formulation · Assigned to Biokine Therapeutics Ltd · Expires 2041-12-29 · 16y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent discloses a composition comprising BL-8040 and at least one other compound with specific relative retention times.

USPTO Abstract

A composition comprising BL-8040 (SEQ ID NO: 1) is disclosed herein, which may be for use in treating a condition treatable by BL-8040. The composition further comprises at least one compound characterized by a relative retention time of from 0.86 to 0.88 and/or a relative retention time of from 0.71 to 0.73 (wherein a relative retention time of BL-8040 is 1) under conditions described herein.

Drugs covered by this patent

Patent Metadata

Patent number
US12268725
Jurisdiction
US
Classification
Formulation
Expires
2041-12-29
Drug substance claim
No
Drug product claim
Yes
Assignee
Biokine Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.